文献速递脑血管病神经重症与神经感染

ATACH 2 试验的血压达标分析

Blood Pressure-Attained Analysis of ATACH 2 Trial.
PubMed 文献 · Stroke · 2018-05-22

本研究基于 ATACH 2 试验的 1000 例脑出血患者,按治疗后 2 小时内收缩压能否降至 140 mmHg 以下及能否维持至 24 小时分组,比较 3 个月死亡或残疾率。结果显示,实现并维持降压者与未降压者的死亡或残疾率相似(相对危险度 0.98,95%CI 0.74-1.29),但神经系统恶化和心脏相关不良事件发生率更高。

要点

  • 脑出血后 2 小时内收缩压降至 140 mmHg 以下并维持至 24 小时,未降低 3 个月死亡或残疾率(相对危险度 0.98,95%CI 0.74-1.29)。
  • 实现并维持收缩压 <140 mmHg 者,24 小时内神经系统恶化率显著更高(10.4%,相对危险度 1.98,95%CI 1.08-3.62)。
  • 实现但未维持收缩压 <140 mmHg 者,24 小时内神经系统恶化率亦显著更高(11.5%,相对危险度 2.08,95%CI 1.15-3.75)。

核心结论

  • 脑出血患者中,实现并维持或仅实现未维持强化收缩压目标者,死亡或残疾率未下降,但神经系统恶化和心脏相关不良事件发生率更高。

研究设计与样本

  • 基于 ATACH 2 试验的 1000 例收缩压 ≥180 mmHg 且在症状发作 4.5 小时内随机化的脑出血患者,按治疗后收缩压达标情况分组分析。

主要发现

  • 与 2 小时内未将收缩压降至 140 mmHg 以下者相比,实现并维持收缩压 <140 mmHg 者的死亡或残疾率相似(相对危险度 0.98,95%CI 0.74-1.29)。
  • 24 小时内神经系统恶化率在实现并维持组为 10.4%(相对危险度 1.98,95%CI 1.08-3.62),在实现但未维持组为 11.5%(相对危险度 2.08,95%CI 1.15-3.75),均显著高于参照组。
  • 7 天内心脏相关不良事件率在实现并维持收缩压 <140 mmHg 组为 11.2%,高于未降压组的 6.4%。

关键数值与推荐

  • 收缩压 <140 mmHg 实现并维持组与未达标组相比,3 个月死亡或残疾(改良 Rankin 量表评分 4-6 分)相对危险度 0.98(95%CI 0.74-1.29)。
  • 24 小时内神经系统恶化:实现并维持组相对危险度 1.98(95%CI 1.08-3.62),实现但未维持组相对危险度 2.08(95%CI 1.15-3.75)。
  • 7 天内心脏相关不良事件率:实现并维持组 11.2% vs 未降压组 6.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We compared the rates of death or disability, defined by modified Rankin Scale score of 4 to 6, at 3 months in patients with intracerebral hemorrhage according to post-treatment systolic blood pressure (SBP)-attained status. METHODS: We divided 1000 subjects with SBP ≥180 mm Hg who were randomized within 4.5 hours of symptom onset as follows: SBP <140 mm Hg achieved or not achieved within 2 hours; subjects in whom SBP <140 mm Hg was achieved within 2 hours were further divided: SBP <140 mm Hg for 21 to 22 hours (reduced and maintained) or SBP was ≥140 mm Hg for at least 2 hours during the period between 2 and 24 hours (reduced but not maintained). RESULTS: Compared with subjects without reduction of SBP <140 mm Hg within 2 hours, subjects with reduction and maintenance of SBP <140 mm Hg within 2 hours had a similar rate of death or disability (relative risk of 0.98; 95% confidence interval, 0.74-1.29). The rates of neurological deterioration within 24 hours were significantly higher in reduced and maintained group (10.4%; relative risk, 1.98; 95% confidence interval, 1.08-3.62) and in reduced but not maintained group (11.5%; relative risk, 2.08; 95% confidence interval, 1.15-3.75) compared with reference group. The rates of cardiac-related adverse events within 7 days were higher among subjects with reduction and maintenance of SBP <140 mmHg compared to subjects without reduction (11.2% versus 6.4%). CONCLUSIONS: No decline in death or disability but higher rates of neurological deterioration and cardiac-related adverse events were observed among intracerebral hemorrhage subjects with reduction with and without maintenance of intensive SBP goals. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01176565.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Qureshi AI, Palesch YY, Foster LD, et al. Blood Pressure-Attained Analysis of ATACH 2 Trial. Stroke. 2018. PMID: 29789395. doi:10.1161/STROKEAHA.117.019845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。